2012
DOI: 10.4161/cc.11.6.19663
|View full text |Cite
|
Sign up to set email alerts
|

Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
25
0

Year Published

2013
2013
2025
2025

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 22 publications
(26 citation statements)
references
References 79 publications
1
25
0
Order By: Relevance
“…Flavopiridol may alter transcription by other mechanisms in addition to CDK9 inhibition or may inhibit other CDKs, although with lower efficacy. Indeed, the phosphorylation of Serine 5 on the CTD of the RNAPII is reduced by flavopiridol via its inhibitory effect on CDK7 in human glioblastoma cells 5 . Furthermore, a recent screen seeking binding inhibitors to a panel of 119 kinases indicated that flavopiridol also binds the transcription regulator Calcium/Calmodulin kinase 1 with higher affinity than other CDKs and CDK-related kinases 31 .…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Flavopiridol may alter transcription by other mechanisms in addition to CDK9 inhibition or may inhibit other CDKs, although with lower efficacy. Indeed, the phosphorylation of Serine 5 on the CTD of the RNAPII is reduced by flavopiridol via its inhibitory effect on CDK7 in human glioblastoma cells 5 . Furthermore, a recent screen seeking binding inhibitors to a panel of 119 kinases indicated that flavopiridol also binds the transcription regulator Calcium/Calmodulin kinase 1 with higher affinity than other CDKs and CDK-related kinases 31 .…”
Section: Discussionmentioning
confidence: 99%
“…So far, several CDKs inhibitor compounds have been developed with a range of selectivity for CDK9: Flavopiridol, 5 Roscovitine, 6 iCDK9, 7 DRB, 8 SNS-032, 9 RGB-286147 10 and AT7515 11 . Flavopiridol, Roscovitine and SNS-032 are the best known CDK9 inhibitors tested in clinical trials, particularly as anticancer agents 12-15 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Once CDKN1A is outside the cell nucleus, it can no longer impose a cell cycle arrest and, therefore, malignant cells recommence to proliferate [141]. A hyperactive PI3K/Akt signaling system is one of the contributing factors that are also responsible for the development of cancer cells with increased resistance to a broad spectrum of chemotherapeutics [136194] and radiotherapy [143150, 155157]. Some of the anticancer drugs that become clinically ineffective comprise paclitaxel [171, 173180], doxorubicin [180182], gefitinib [152, 183187], imatinib [186, 188192], and flavopiridol [193, 194].…”
Section: Abnormal Akt-related Pathways In Resistance To Cancer Thementioning
confidence: 99%
“…A hyperactive PI3K/Akt signaling system is one of the contributing factors that are also responsible for the development of cancer cells with increased resistance to a broad spectrum of chemotherapeutics [136194] and radiotherapy [143150, 155157]. Some of the anticancer drugs that become clinically ineffective comprise paclitaxel [171, 173180], doxorubicin [180182], gefitinib [152, 183187], imatinib [186, 188192], and flavopiridol [193, 194]. The clinical and/or preclinical studies on the Akt pathway-mediated enhanced resistance to chemo- and/or radiotherapy were conducted on several types of human hematological tumors [195198] and human epithelial malignancies [143, 147160].…”
Section: Abnormal Akt-related Pathways In Resistance To Cancer Thementioning
confidence: 99%